Phibro Animal Health vs Zoetis
PAHC and ZTS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PAHC and ZTS compare
Zoetis is the larger company, worth 24 times as much as Phibro Animal Health ($34.5B against $1.4B).
On earnings, Zoetis is cheaper: it trades at 13.7× trailing earnings, against 14.4× for Phibro Animal Health.
Phibro Animal Health grew revenue faster over the last twelve months (17.1% versus 1.5% for Zoetis).
Zoetis keeps more of each dollar of sales as profit, with a net margin of 27.5% compared with 6.6% at Phibro Animal Health.
Both pay dividends: Phibro Animal Health yields 1.4% and Zoetis 1.9%.
Phibro Animal Health scores higher on the StockData Score (22 against 17 for Zoetis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PAHC | ZTS |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | $34.5B |
| Share price | $34.92 | $83.48 |
| Change, 1 year | −22.6% | −30.9% |
| Change, 5 years | 67.2% | −61.9% |
| Beta (5Y) | −0.07 | 0.06 |
| Employees | 2,605 | 15K |
| StockData Score | ||
| Total score | 22 (better) | 17 |
| Valuation score | 5 | 5 |
| Growth score | 6 (better) | 2 |
| Performance score | 6 (better) | 5 |
| Health score | 2 | 3 (better) |
| Dividend score | 3 (better) | 2 |
| Valuation | ||
| P/E | 14.4× | 13.7× (better) |
| P/S | 0.9× (better) | 3.6× |
| P/B | 3.7× (better) | 11.0× |
| EV/EBITDA | 5.4× (better) | 10.5× |
| P/FCF | 144× | 14.9× (better) |
| PEG | 0.32 (better) | 1.34 |
| FCF yield | 0.70% | 6.7% (better) |
| Fair value | $65.12 | $154.11 |
| Margin of safety | 46.4% (better) | 45.8% |
| Growth | ||
| Revenue growth (TTM) | 17.1% (better) | 1.5% |
| Revenue growth, 5Y average | 12.7% (better) | 7.2% |
| Net income growth (TTM) | 107% (better) | 0.96% |
| EPS growth (TTM) | 104% (better) | 5.6% |
| EPS growth, 5Y average | 12.6% (better) | 12.0% |
| Profitability | ||
| Gross margin | 33.8% | 71.5% (better) |
| Operating margin | 12.8% | – |
| Net margin | 6.6% | 27.5% (better) |
| FCF margin | 0.65% | 24.3% (better) |
| Return on equity | 29.7% | 64.4% (better) |
| Return on invested capital | 24.7% | – |
| Financial health | ||
| Debt / equity | – | 2.87 |
| Net debt / EBITDA | – | 1.85 |
| Interest coverage | 4.2× | – |
| Current ratio | 2.96 | 3.08 (better) |
| Altman Z-score | 3.02 | 4.07 (better) |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | 1.4% | 1.9% (better) |
| Payout ratio | 19.5% | – |
| Years of dividend growth | 0 | 13 (better) |
| Dividend growth, 5Y average | 0.00% | 19.0% (better) |
| Buyback yield | – | 10.6% |
| Shareholder yield | 1.4% | 12.5% (better) |
| Ownership | ||
| Held by institutions | 51.8% | 96.1% |
| Held by insiders | 98.9% | 0.08% |
| Insider net buying, 12 months | −$23.0M | −$1.7M (better) |
| Superinvestors holding | – | 3 |
| Short interest, % of float | 233% | 4.1% |
Go deeper
- PAHC stock overview
- PAHC income statement
- PAHC valuation and score
- ZTS stock overview
- ZTS income statement
- ZTS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.